Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Related Party Agreements (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 09, 2017	Feb. 28, 2015	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Nov. 08, 2022
Research and Development Expense			$ 2,392	$ 1,215
Fortress [Member]
Percentage of Fully-diluted Outstanding Equity		2.50%
Percentage of Equity or Debt Fnancing		2.50%
Stock Issued During Period, Shares, New Issues (in shares)			5,543	1,912
Stock Issuable During Period, Shares, Financing Equity Fee (in shares)			5,513
Stock Issued During Period, Shares, Annual Equity Fee (in shares)			22,476	3,085
Fortress [Member] \| Avenue Baergic Founders Agreement [Member]
Excess in Net Assets Value	$ 100,000
Fortress [Member] \| Annual Equity Fees [Member]
Research and Development Expense					$ 300	$ 300
Fortress [Member] \| Management Services Agreement [Member]
Costs and Expenses			$ 100	$ 100
Fortress [Member] \| Research and Development Expense [Member] \| Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage		50.00%
Fortress [Member] \| General and Administrative Expense [Member] \| Management Services Agreement [Member]
Service Provided, Expense Recorded, Percentage		50.00%
BaergicBio, Inc.[Member] \| Avenue Baergic Founders Agreement [Member]
Percentage of Equity Fee							2.50%
Percentage Of Additional Consideration Of Equity Fee						2.50%
Percentage Considered For The Calculation Of One-Time Fee						4.50%
Term of Agreement (Year)	5 years
Annual Consulting Fee	$ 500
Increase in Annual Consulting Fee	$ 1,000